Advertisement

Topics

FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount

02:28 EDT 2 Aug 2017 | RTTNews

Today's Daily Dose brings you news about FDA approval of AML therapy developed by Agios and Celgene; expanding indications of Bristol-Myers' immunotherapy wonder drug Opdivo and Gilead's hepatitis C drug Epclusa; Corcept's near-term catalysts; Genomic's financial health and reduction in Ocular's workforce.

Original Article: FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount

NEXT ARTICLE

More From BioPortfolio on "FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount"

Quick Search
Advertisement
 

Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...